Novo Nordisk’s Wegovy pill beats forecasts as it battles Lilly
Sales of Novo Nordisk's Wegovy pill were kr5.39 billion, up 53% from Q2 and above the kr4.62 billion forecast in the company-compiled consensus.
We haven't written up this one. Free Malaysia Today has the full story — the link below goes straight to it.